Advancing patient health in low- and middle-income countries
Our vision to transform patients' lives through science extends to all patients, regardless of where they live in the world or ability to pay. We are committed to expanding timely access to BMS medicines to help people in low- and middle-income countries live healthier lives.
”Access to potentially life-saving innovative medicines is very limited in some parts of the world, leaving patients with few treatment options for serious diseases like cancer. Bristol Myers Squibb believes patients who can benefit from our medicines should have access to them. Our ASPIRE strategy is an important step toward accelerating and expanding patient access to these much-needed treatments.
Chris Boerner, PhD
Board Chair and Chief Executive Officer at Bristol Myers Squibb
”As part of our commitment to advancing global health equity, BMS is dedicated to creating equitable access to our innovative treatments for medically underserved patients around the world. By pursuing access pathways that are tailored to each country’s healthcare infrastructure, we aim to address systemic barriers to ensure more patients can benefit from our medicines.
Adam Lenkowsky
Executive Vice President and Chief Commercialization Officer, Bristol Myers Squibb
We're meeting our commitments through tailored, sustainable strategies
We have a long-standing commitment to promote health equity and help people in underserved communities access the care and medicines they need. We’ve built on this commitment with our 10-year strategy known as ASPIRE, to help reach more patients and communities in LMICs.
